別包装 |
あり
|
純度 |
>=98%
|
分子量 |
925.46
|
CAS RN® |
388082-78-8
|
化合物の概要 |
EGFR inhibitor.
|
構造 |
C26H26ClFN4O4S 2C7H8O3S H2O
|
溶媒 |
Slightly in DMSO
|
使用目的 |
Lapatinib is an inhibitor of EGFR/HER2 (ErbB2) that is currently in clinical trials as a co-administered treatment with other chemotherapeutics. Lapatinib exhibits anticancer chemotherapeutic benefit, inducing apoptosis in breast cancer cells. This compound also downregulates expression of thymidylate synthase in vitro.
|
その他 |
[融点]236-259℃
|
参考文献 |
Janni W, Sarosiek T, Karaszewska B, et al. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2014 Jan 9. [Epub ahead of print]. PMID: 24402830.Kostyal D, Welt RS, Danko J, et al. Trastuzumab and lapatinib modulation of HER2 tyrosine/threonine phosphorylation and cell signaling. Med Oncol. 2012 Sep;29(3):1486-94. PMID: 21769502.Kim HP, Yoon YK, Kim JW, et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One. 2009 Jun 16;4(6):e5933. PMID: 19529774.
|
|
メーカー |
品番 |
包装 |
LKT
|
L0360
|
25 MG
|
※表示価格について
当社在庫 |
なし
|
納期目安 |
1週間程度
|
保存温度 |
4℃
|
|